Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 97

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Translating bacteriophage-derived depolymerases into antibacterial therapeutics: Challenges and prospects

Wang, Honglan, Liu, Yannan, Bai, Changqing, Leung, Sharon Shui Yee · 2024 · Acta Pharmaceutica Sinica B

Abstract

Predatory bacteriophages have evolved a vast array of depolymerases for bacteria capture and deprotection. These depolymerases are enzymes responsible for degrading diverse bacterial surface carbohydrates. They are exploited as antibiofilm agents and antimicrobial adjuvants while rarely inducing bacterial resistance, making them an invaluable asset in the era of antibiotic resistance. Numerous depolymerases have been investigated preclinically, with evidence indicating that depolymerases with appropriate dose regimens can safely and effectively combat different multidrug-resistant pathogens in animal infection models. Additionally, some formulation approaches have been developed for improved stability and activity of depolymerases. However, depolymerase formulation is limited to liquid dosage form and remains in its infancy, posing a significant hurdle to their clinical translation, compounded by challenges in their applicability and manufacturing. Future development must address these obstacles for clinical utility. Here, after unravelling the history, diversity, and therapeutic use of depolymerases, we summarized the preclinical efficacy and existing formulation findings of recombinant depolymerases. Finally, the challenges and perspectives of depolymerases as therapeutics for humans were assessed to provide insights for their further development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.apsb.2023.08.017

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 95

  1. Christaki, 2020, Antimicrobial resistance in bacteria: mechanisms, evolution, and persistence, J Mol Evol, 88, 26, 10.1007/s00239-019-09914-3 · DOI · Paper page
  2. Baker, 2018, Technologies to address antimicrobial resistance, Proc Natl Acad Sci U S A, 115, 12887, 10.1073/pnas.1717160115 · DOI · Paper page
  3. Mousavi, 2021, Bacteriophage as a novel therapeutic weapon for killing colistin-resistant multi-drug-resistant and extensively drug-resistant Gram-negative bacteria, Curr Microbiol, 78, 4023, 10.1007/s00284-021-02662-y · DOI
  4. Knecht, 2020, Diversity and function of phage encoded depolymerases, Front Microbiol, 10, 2949, 10.3389/fmicb.2019.02949 · DOI · Paper page
  5. Koskella, 2014, Bacteria-phage coevolution as a driver of ecological and evolutionary processes in microbial communities, FEMS Microbiol Rev, 38, 916, 10.1111/1574-6976.12072 · DOI · Paper page
  6. Abarquero, 2021, Study of exopolysaccharides from lactic acid bacteria and their industrial applications: a review, Int J Food Sci Technol, 57, 16, 10.1111/ijfs.15227 · DOI
  7. Hoiby, 2017, A short history of microbial biofilms and biofilm infections, APMIS, 125, 272, 10.1111/apm.12686 · DOI · Paper page
  8. Flemming, 2010, The biofilm matrix, Nat Rev Microbiol, 8, 623, 10.1038/nrmicro2415 · DOI · Paper page
  9. Labrie, 2010, Bacteriophage resistance mechanisms, Nat Rev Microbiol, 8, 317, 10.1038/nrmicro2315 · DOI · Paper page
  10. Oechslin, 2018, Resistance development to bacteriophages occurring during bacteriophage therapy, Viruses, 10, 351, 10.3390/v10070351 · DOI · Paper page
  11. Chen, 2022, Phage-derived depolymerase as an antibiotic adjuvant against multidrug-resistant Acinetobacter baumannii, Front Microbiol, 13
  12. Topka-Bielecka, 2021, Bacteriophage-derived depolymerases against bacterial biofilm, Antibiotics, 10, 175, 10.3390/antibiotics10020175 · DOI · Paper page
  13. Liston, 2018, Periplasmic depolymerase provides insight into ABC transporter-dependent secretion of bacterial capsular polysaccharides, Proc Natl Acad Sci U S A, 115, E4870, 10.1073/pnas.1801336115 · DOI
  14. Twort, 1915, An investigation on the nature of ultra-microscopic viruses, Lancet, 186, 1241, 10.1016/S0140-6736(01)20383-3 · DOI · Paper page
  15. d'Herelle, 1917, An invisible microbe that is antagonistic to the dysentery bacillus, C R Acad Sci, 165, 373
  16. Asheshov, 1924, Experimental studies on the bacteriophage, J Infect Dis, 34, 536, 10.1093/infdis/34.5.536 · doi:10.1093/infdis/34.5.536
  17. Sertic, 1929, Origine de la lysine d'une race du bacteriophage, Compt Rend Soc Biol, 100, 477
  18. Sertic, 1937, Sur la sensibilite d'une souche d'Escherichia coli au bactdriophage, en relation avec les caracteres antig6niques, Compt Rend Soc Biol, 126, 734
  19. Adams, 1956, An enzyme produced by a phage-host cell system: II. the properties of the polysaccharide depolymerase, Virology, 2, 719, 10.1016/0042-6822(56)90054-X · DOI
  20. Stirm, 1971, Bacteriophage particles with endo-glycosidase activity, J Virol, 8, 343, 10.1128/jvi.8.3.343-346.1971 · doi:10.1128/jvi.8.3.343-346.1971
  21. Steinbacher, 1996, Crystal structure of phage P22 tailspike protein complexed with Salmonella sp. O-antigen receptors, Proc Natl Acad Sci U S A, 93, 10584, 10.1073/pnas.93.20.10584 · DOI · Paper page
  22. Latka, 2019, Modeling the architecture of depolymerase-containing receptor binding proteins in Klebsiella phages, Front Microbiol, 10, 2649, 10.3389/fmicb.2019.02649 · DOI
  23. Clarke, 2000, Cloning, expression, and purification of the K5 capsular polysaccharide lyase (KflA) from coliphage K5A: evidence for two distinct K5 lyase enzymes, J Bacteriol, 182, 3761, 10.1128/JB.182.13.3761-3766.2000 · doi:10.1128/jb.182.13.3761-3766.2000
  24. Leiman, 2008, Evolution of a new enzyme activity from the same motif fold, Mol Microbiol, 69, 287, 10.1111/j.1365-2958.2008.06241.x · DOI
  25. Barbirz, 2008, Crystal structure of Escherichia coli phage HK620 tailspike: podoviral tailspike endoglycosidase modules are evolutionarily related, Mol Microbiol, 69, 303, 10.1111/j.1365-2958.2008.06311.x · DOI
  26. Mushtaq, 2004, Prevention and cure of systemic Escherichia coli K1 infection by modification of the bacterial phenotype, Antimicrob Agents Chemother, 48, 1503, 10.1128/AAC.48.5.1503-1508.2004 · DOI
  27. Waseh, 2010, Orally administered P22 phage tailspike protein reduces salmonella colonization in chickens: prospects of a novel therapy against bacterial infections, PLoS One, 5, 10.1371/journal.pone.0013904 · DOI
  28. Bansal, 2014, Depolymerase improves gentamicin efficacy during Klebsiella pneumoniae induced murine infection, BMC Infect Dis, 14, 456, 10.1186/1471-2334-14-456 · DOI
  29. Shahed-Al-Mahmud, 2021, Phage phiAB6-borne depolymerase combats Acinetobacter baumannii biofilm formation and infection, Antibiotics, 10, 279, 10.3390/antibiotics10030279 · DOI
  30. Pan, 2015, Identification of capsular types in carbapenem-resistant Klebsiella pneumoniae strains by wzc sequencing and implications for capsule depolymerase treatment, Antimicrob Agents Chemother, 59, 1038, 10.1128/AAC.03560-14 · DOI
  31. Mostowy, 2018, Diversity-generating machines: genetics of bacterial sugar-coating, Trends Microbiol, 26, 1008, 10.1016/j.tim.2018.06.006 · DOI
  32. Pires, 2016, Bacteriophage-encoded depolymerases: their diversity and biotechnological applications, Appl Microbiol Biotechnol, 100, 2141, 10.1007/s00253-015-7247-0 · DOI · Paper page
  33. Drulis-Kawa, 2015, Bacteriophages and phage-derived proteins—application approaches, Curr Med Chem, 22, 1757, 10.2174/0929867322666150209152851 · DOI · Paper page
  34. Nobrega, 2018, Targeting mechanisms of tailed bacteriophages, Nat Rev Microbiol, 16, 760, 10.1038/s41579-018-0070-8 · DOI · Paper page
  35. Squeglia, 2020, Structural and functional studies of a Klebsiella phage capsule depolymerase tailspike: mechanistic insights into capsular degradation, Structure, 28, 613, 10.1016/j.str.2020.04.015 · DOI
  36. Latka, 2017, Bacteriophage-encoded virion-associated enzymes to overcome the carbohydrate barriers during the infection process, Appl Microbiol Biotechnol, 101, 3103, 10.1007/s00253-017-8224-6 · DOI · Paper page
  37. Latka, 2021, Engineering the modular receptor-binding proteins of Klebsiella phages switches their capsule serotype specificity, mBio, 12, 10.1128/mBio.00455-21 · DOI
  38. Yan, 2014, Bacteriophage polysaccharide depolymerases and biomedical applications, BioDrugs, 28, 265, 10.1007/s40259-013-0081-y · DOI · Paper page
  39. Patro, 2020, A unified platform to distinguish Klebsiella species K- and O-antigen types, model antigen structures and identify hypervirulent strains, Sci Rep, 10, 10.1038/s41598-020-73360-1 · DOI
  40. Oliveira, 2022, Exploiting phage-derived carbohydrate depolymerases for combating infectious diseases, Trends Microbiol, 30, 707, 10.1016/j.tim.2022.05.002 · doi:10.1016/j.tim.2022.05.002
  41. Reuter, 2020, Approaches to optimize therapeutic bacteriophage and bacteriophage-derived products to combat bacterial infections, Virus Gene, 56, 136, 10.1007/s11262-020-01735-7 · DOI
  42. Drulis-Kawa, 2012, Learning from bacteriophages—advantages and limitations of phage and phage-encoded protein applications, Curr Protein Pept Sci, 13, 699, 10.2174/138920312804871193 · DOI · Paper page
  43. Li, 2017, Antibiofilm agents: a new perspective for antimicrobial strategy, J Microbiol, 55, 753, 10.1007/s12275-017-7274-x · DOI · Paper page
  44. Taraszkiewicz, 2013, Innovative strategies to overcome biofilm resistance, BioMed Res Int, 2013, 10.1155/2013/150653 · DOI · Paper page
  45. Limoli, 2015, Bacterial extracellular polysaccharides in biofilm formation and function, Microbiol Spectr, 3, 10, 10.1128/microbiolspec.MB-0011-2014 · DOI · Paper page
  46. Hernandez-Morales, 2018, Genomic and biochemical characterization of Acinetobacter podophage Petty reveals a novel lysis mechanism and tail-associated depolymerase activity, J Virol, 92, 10.1128/JVI.01064-17 · DOI
  47. Gutiérrez, 2012, Genomic characterization of two Staphylococcus epidermidis bacteriophages with anti-biofilm potential, BMC Genom, 13, 228, 10.1186/1471-2164-13-228 · DOI
  48. Gutiérrez, 2015, Role of the pre-neck appendage protein (Dpo7) from phage vB_SepiS-phiIPLA7 as an anti-biofilm agent in Staphylococcal species, Front Microbiol, 6, 1315, 10.3389/fmicb.2015.01315 · DOI
  49. Olsen, 2018, Synergistic removal of static and dynamic Staphylococcus aureus biofilms by combined treatment with a bacteriophage endolysin and a polysaccharide depolymerase, Viruses, 10, 438, 10.3390/v10080438 · DOI
  50. Chai, 2014, Application of bacteriophage-borne enzyme combined with chlorine dioxide on controlling bacterial biofilm, LWT--Food Sci Technol, 59, 1159, 10.1016/j.lwt.2014.06.033 · doi:10.1016/j.lwt.2014.06.033
  51. Oliveira, 2017, Synergistic antimicrobial interaction between honey and phage against Escherichia coli biofilms, Front Microbiol, 8, 2407, 10.3389/fmicb.2017.02407 · DOI
  52. Tait, 2002, The efficacy of bacteriophage as a method of biofilm eradication, Biofouling, 18, 305, 10.1080/0892701021000034418 · DOI
  53. Lu, 2007, Dispersing biofilms with engineered enzymatic bacteriophage, Proc Natl Acad Sci U S A, 104, 11197, 10.1073/pnas.0704624104 · DOI · Paper page
  54. Projan, 2004, Phage-inspired antibiotics?., Nat Biotechnol, 22, 167, 10.1038/nbt0204-167 · DOI
  55. Pires, 2017, Phage therapy as an alternative or complementary strategy to prevent and control biofilm-related infections, Curr Opin Microbiol, 39, 48, 10.1016/j.mib.2017.09.004 · DOI · Paper page
  56. Hughes, 1998, Biofilm susceptibility to bacteriophage attack: the role of phage-borne polysaccharide depolymerase, Microbiology (Read), 144, 3039, 10.1099/00221287-144-11-3039 · DOI · Paper page
  57. Hanlon, 2001, Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms, Appl Environ Microbiol, 67, 2746, 10.1128/AEM.67.6.2746-2753.2001 · DOI · Paper page
  58. Bansal, 2015, Aeromonas punctata derived depolymerase improves susceptibility of Klebsiella pneumoniae biofilm to gentamicin, BMC Microbiol, 15, 119, 10.1186/s12866-015-0455-z · DOI
  59. Wu, 2019, A novel polysaccharide depolymerase encoded by the phage SH-KP152226 confers specific activity against multidrug-resistant Klebsiella pneumoniae via biofilm degradation, Front Microbiol, 10, 2768, 10.3389/fmicb.2019.02768 · DOI · Paper page
  60. Majkowska-Skrobek, 2018, Phage-borne depolymerases decrease Klebsiella pneumoniae resistance to innate defense mechanisms, Front Microbiol, 9, 2517, 10.3389/fmicb.2018.02517 · DOI
  61. Oliveira, 2020, A tailspike with exopolysaccharide depolymerase activity from a new Providencia stuartii phage makes multidrug-resistant bacteria susceptible to serum-mediated killing, Appl Environ Microbiol, 86, 10.1128/AEM.00073-20 · DOI
  62. Abdelkader, 2022, The specific capsule depolymerase of phage PMK34 sensitizes Acinetobacter baumannii to serum killing, Antibiotics, 11, 677, 10.3390/antibiotics11050677 · DOI
  63. Oliveira, 2019, K2 Capsule depolymerase is highly stable, is refractory to resistance, and protects larvae and mice from Acinetobacter baumannii sepsis, Appl Environ Microbiol, 85, 10.1128/AEM.00934-19 · DOI
  64. Smug, 2022, PhREEPred: phage resistance emergence prediction web tool to foresee encapsulated bacterial escape from phage cocktail treatment, J Mol Biol, 434, 10.1016/j.jmb.2022.167670 · doi:10.1016/j.jmb.2022.167670
  65. Majkowska-Skrobek, 2021, The evolutionary trade-offs in phage-resistant Klebsiella pneumoniae entail cross-phage sensitization and loss of multidrug resistance, Environ Microbiol, 23, 7723, 10.1111/1462-2920.15476 · DOI
  66. Danis-Wlodarczyk, 2021, Treating bacterial infections with bacteriophage-based enzybiotics: in vitro, in vivo and clinical application, Antibiotics, 10, 1497, 10.3390/antibiotics10121497 · DOI
  67. Lin, 2014, Isolation of a bacteriophage and its depolymerase specific for K1 capsule of Klebsiella pneumoniae: implication in typing and treatment, J Infect Dis, 210, 1734, 10.1093/infdis/jiu332 · DOI · Paper page
  68. Volozhantsev, 2022, Comparison of the therapeutic potential of bacteriophage KpV74 and phage-derived depolymerase (beta-glucosidase) against Klebsiella pneumoniae capsular type K2, Virus Res, 322, 10.1016/j.virusres.2022.198951 · DOI
  69. Li, 2022, Identification of a phage-derived depolymerase specific for KL47 capsule of Klebsiella pneumoniae and its therapeutic potential in mice, Virol Sin, 37, 538, 10.1016/j.virs.2022.04.005 · DOI
  70. Wang, 2019, Protective and therapeutic application of the depolymerase derived from a novel KN1 genotype of Klebsiella pneumoniae bacteriophage in mice, Res Microbiol, 170, 156, 10.1016/j.resmic.2019.01.003 · DOI
  71. Majkowska-Skrobek, 2016, Capsule-targeting depolymerase, derived from Klebsiella KP36 phage, as a tool for the development of anti-virulent strategy, Viruses, 8, 324, 10.3390/v8120324 · DOI
  72. Volozhantsev, 2020, Characterization and therapeutic potential of bacteriophage-encoded polysaccharide depolymerases with beta galactosidase activity against Klebsiella pneumoniae K57 capsular type, Antibiotics, 9, 732, 10.3390/antibiotics9110732 · doi:10.3390/antibiotics9110732
  73. Gorodnichev, 2021, Novel Klebsiella pneumoniae K23-specific bacteriophages from different families: similarity of depolymerases and their therapeutic potential, Front Microbiol, 12, 10.3389/fmicb.2021.669618 · doi:10.3389/fmicb.2021.669618
  74. Liu, 2019, The capsule depolymerase Dpo48 rescues Galleria mellonella and mice from Acinetobacter baumannii systemic infections, Front Microbiol, 10, 545, 10.3389/fmicb.2019.00545 · DOI
  75. Wang, 2020, Identification of a novel Acinetobacter baumannii phage-derived depolymerase and its therapeutic application in mice, Front Microbiol, 11, 1407, 10.3389/fmicb.2020.01407 · doi:10.3389/fmicb.2020.01407
  76. Mushtaq, 2005, Treatment of experimental Escherichia coli infection with recombinant bacteriophage-derived capsule depolymerase, J Antimicrob Chemother, 56, 160, 10.1093/jac/dki177 · DOI
  77. Lin, 2017, Therapeutic application of phage capsule depolymerases against K1, K5, and K30 capsulated E. coli in mice, Front Microbiol, 8, 2257, 10.3389/fmicb.2017.02257 · doi:10.3389/fmicb.2017.02257
  78. Lin, 2018, Antibiotic therapy using phage depolymerases: robustness across a range of conditions, Viruses, 10, 622, 10.3390/v10110622 · doi:10.3390/v10110622
  79. Chen, 2020, A novel tail-associated O91-specific polysaccharide depolymerase from a podophage reveals lytic efficacy of Shiga toxin-producing Escherichia coli, Appl Environ Microbiol, 86, 10.1128/AEM.00145-20 · DOI
  80. Olszak, 2017, The O-specific polysaccharide lyase from the phage LKA1 tailspike reduces Pseudomonas virulence, Sci Rep, 7, 10.1038/s41598-017-16411-4 · DOI
  81. Sumrall, 2021, An enzybiotic regimen for the treatment of methicillin-resistant Staphylococcus aureus orthopaedic device-related infection, Antibiotics, 10, 1186, 10.3390/antibiotics10101186 · DOI
  82. M Campos, 2020, Global priority pathogens: virulence, antimicrobial resistance and prospective treatment options, Future Microbiol, 15, 649, 10.2217/fmb-2019-0333 · DOI
  83. Ma, 2019, Considerations and caveats in combating ESKAPE pathogens against nosocomial infections, Adv Sci, 7
  84. Ryan, 2011, Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy, J Pharm Pharmacol, 63, 1253, 10.1111/j.2042-7158.2011.01324.x · DOI · Paper page
  85. Liu, 2019, Identification and characterization of capsule depolymerase Dpo48 from Acinetobacter baumannii phage IME200, PeerJ, 7
  86. Kassa, 2012, Thermal treatment of the bacteriophage lysate of Klebsiella pneumoniae B5055 as a step for the purification of capsular depolymerase enzyme, J Virol Methods, 179, 135, 10.1016/j.jviromet.2011.10.011 · DOI
  87. Montanari, 2017, Hyaluronan-cholesterol nanohydrogels: characterisation and effectiveness in carrying alginate lyase, N Biotech, 37, 80, 10.1016/j.nbt.2016.08.004 · DOI
  88. Dunstan, 2021, Mechanistic insights into the capsule-targeting depolymerase from a Klebsiella pneumoniae bacteriophage, Microbiol Spectr, 9, 10.1128/Spectrum.01023-21 · DOI
  89. Libertucci, 2019, The role of the microbiota in infectious diseases, Nat Microbiol, 4, 35, 10.1038/s41564-018-0278-4 · DOI · Paper page
  90. Gutierrez, 2018, Are phage lytic proteins the secret weapon to kill Staphylococcus aureus?., mBio, 9, 10.1128/mBio.01923-17 · DOI
  91. 2008, Structural Genomics Consortium, China Structural Genomics Consortium, Northeast Structural Genomics Consortium, Graslund S, Nordlund P, Weigelt J, et al. Protein production and purification, Nat Methods, 5, 135
  92. Klimyuk, 2014, Production of recombinant antigens and antibodies in Nicotiana benthamiana using 'magnifection' technology: GMP-compliant facilities for small- and large-scale manufacturing, Curr Top Microbiol Immunol, 375, 127
  93. Frokjaer, 2005, Protein drug stability: a formulation challenge, Nat Rev Drug Discov, 4, 298, 10.1038/nrd1695 · DOI · Paper page
  94. Cornforth, 2018, Pseudomonas aeruginosa transcriptome during human infection, Proc Natl Acad Sci U S A, 115, E5125, 10.1073/pnas.1717525115 · DOI · Paper page
  95. Bjarnsholt, 2022, The importance of understanding the infectious microenvironment, Lancet Infect Dis, 22, e88, 10.1016/S1473-3099(21)00122-5 · DOI · Paper page

Cited by

Metadata

Authors
Wang, H., Liu, Y., Bai, C., & Leung, S. S. Y.
Venue
Acta Pharmaceutica Sinica B
Publisher
Elsevier BV
Published
2024-01
Volume
14
Issue
1
Pages
155-169
ISSN
2211-3835
Cited by
97
References
3
Language
en
Licence
Funders
Research Grants Council, University Grants Committee (14112921)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.